Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies

Cancer Treatment Reviews

Volumn 40, Issue 4, 2014, Pages 513-522

  Sideras, K ^a   Braat, H ^a   Kwekkeboom, J ^a   van Eijck, C H ^a   Peppelenbosch, M P ^a   Sleijfer, S ^a   Bruno, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fibroblasts; Immune inhibitory ligands; Immune system; Immunotherapy; Pancreatic cancer; Review; T regulatory cells; Th1; Th2; Vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALECTIN; GEMCITABINE; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; MESOTHELIN; REACTIVE OXYGEN METABOLITE; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELL VACCINE; VASCULOTROPIN;

CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; FIBROBLAST; HELPER CELL; IMMUNE SYSTEM; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

FIBROBLASTS; IMMUNE INHIBITORY LIGANDS; IMMUNE SYSTEM; IMMUNOTHERAPY; PANCREATIC CANCER; REVIEW; T REGULATORY CELLS; TH1; TH2; VACCINATION;

ANIMALS; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 84896702241     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.11.005     Document Type: Review

References (103)

1. Jemal A., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
3. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5(4):263-274.
4. Qin F.X. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol Immunol 2009, 6(1):3-13.
5. Pedroza-Gonzalez A., et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2012, 57(1):183-194.
6. Ikemoto T., et al. Clinical roles of increased populations of Foxp3+CD4 T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006, 33(4):386-390.
7. Hiraoka N., et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12(18):5423-5434.
8. Yamamoto T., et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012, 41(3):409-415.
9. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010, 59(10):1593-1600.
10. Zhao F., et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009, 128(1):141-149.
11. Gabitass R.F., et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011, 60(10):1419-1430.
12. Schmieder A., et al. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol 2012, 22(4):289-297.
13. Siveen K.S., Kuttan G. Role of macrophages in tumour progression. Immunol Lett 2009, 123(2):97-102.
14. Esposito I., et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004, 57(6):630-636.
15. Kurahara H., et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011, 167(2):e211-e219.
16. Schmitz-Winnenthal F.H., et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005, 65(21):10079-10087.
17. Fukunaga A., et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004, 28(1):e26-e31.
18. Tassi E., et al. Carcinoembryonic antigen-specific but not antiviral CD4 T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 2008, 181(9):6595-6603.
19. Bellone G., et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999, 155(2):537-547.
20. Yamamoto T., et al. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res 2012, 173(2):299-308.
21. Tjomsland V., et al. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS One 2010, 5(10):e13441.
22. Pandha H., et al. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol 2007, 148(1):127-135.
23. Aparicio-Pages M.N., et al. Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. J Clin Lab Immunol 1991, 35(1):27-32.
24. Duan X., et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011, 28(2):466-474.
25. Davis M., et al. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother 2012, 35(8):629-640.
26. Inman B.A., et al. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007, 7(1):15-30.
27. Geng L., et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 2008, 134(9):1021-1027.
28. Nomi T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13(7):2151-2157.
29. Shoji Y., et al. The CD40-CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma. J Surg Oncol 2011, 103(3):230-238.
30. Loos M., et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009, 9:463.
31. Yamato I., et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009, 101(10):1709-1716.
32. Hinz S., et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007, 67(17):8344-8350.
33. Teraoka H., et al. TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion. Int J Oncol 2001, 19(4):709-715.
34. Sawada T., et al. TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer. Adv Med Sci 2006, 51:60-65.
35. Bellone G., et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006, 55(6):684-698.
36. Fallarino F., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006, 176(11):6752-6761.
37. Witkiewicz A., et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008, 206(5):849-854. [discussion 854-6].
38. Cooper D., et al. Multiple functional targets of the immunoregulatory activity of galectin-1: control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol 2010, 480:199-244.
39. Kuramitsu Y., et al. Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 2010, 30(9):3367-3372.
40. Chung J.C., et al. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J Surg 2008, 78(4):245-251.
41. Fitzner B., et al. Galectin-1 is an inductor of pancreatic stellate cell activation. Cell Signal 2005, 17(10):1240-1247.
42. Tang D., et al. High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 2012, 130(10):2337-2348.
43. Chen R., et al. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther 2012, 13(10):899-907.
44. Dardalhon V., et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol 2010, 185(3):1383-1392.
45. Peng W., et al. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 2008, 68(17):7228-7236.
46. Xie L., et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol 2012, 138(6):1035-1043.
47. Song S., et al. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012, 7(8):e42699.
48. Erez N., et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17(2):135-147.
49. Kraman M., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330(6005):827-830.
50. Shi M., et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol 2012, 18(8):840-846.
51. Weden S., et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011, 128(5):1120-1128.
52. Abou-Alfa G.K., et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011, 34(3):321-325.
53. Muscarella P., et al. A randomized, placebo controlled, double blind, multicenter phase 2 adjuvant trial of the efficacy, immunogeneicity, and safety of GI-4000 plus Gem vs Gem alone in patients with resected pancreas cancer with activating Ras mutations/survival and immunology analysis of the R1 Subgroup. J Clin Oncol 2012, 30(Suppl.). [abstr #e14501].
54. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00300950&Search=Search.
55. Hamanaka Y., et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003, 103(1):97-100.
56. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00088660&Search=Search.
57. [homepage on the Internet]. Identifier: UMIN000005248. Available from: https://www.upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=history&action=list&type=summary&recptno=R000006238&language=E.
58. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=+NCT01417000&Search=Search.
59. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00655785&Search=Search.
60. [homepage on the Internet]. Identifier: UMIN000001664. Available from: https://www.upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000002006&language=E.
61. Bernhardt S.L., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95(11):1474-1482.
62. Buanes T., et al. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). ASCO Annu Conf 2009, 27(15s). [abstr 4601].
63. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01526473&Search=Search.
64. Jaffee E.M., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19(1):145-156.
65. Lutz E., et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg 2011, 253(2):328-335.
66. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00305760&Search=Search.
67. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00389610&Search=Search.
68. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00727441&Search=Search.
69. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01595321&Search=Search.
70. Lepisto A.J., et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008, 6(B):955-964.
71. Van Nuffel A.M., et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4 and CD8 T cells in melanoma patients. Mol Ther 2012, 20(5):1063-1074.
72. Rosenberg S.A., Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(Suppl. 2):14639-14645.
73. Morgan R.A., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
74. Johnson L.A., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
75. Kochenderfer J.N., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119(12):2709-2720.
76. Lamers C.H., et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117(1):72-82.
77. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013, 3(4):388-398.
78. Chmielewski M., et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012, 143(4). [p. 1095-107.e2].
79. Kondo H., et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 2008, 28(1B):379-387.
80. Kawaoka T., et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep 2008, 20(1):155-163.
81. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/show/NCT01723306?term=pancreatic+cancer%2C+tcr&rank=4.
82. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01583686&Search=Search.
83. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.
84. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
85. Royal R.E., et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010, 33(8):828-833.
86. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://clinicaltrials.gov/ct2/results?term=NCT00836407+Search=Search.
87. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00556023+&Search=Search.
88. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01473940&Search=Search.
89. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465.
90. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369(2):134-144.
91. Topalian S.L., Brahmer J.R., Hodi F.S. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: clinical activity, safety, and a potential biomarker for response. ASCO Annu Conf 2012, 30(15s):144s.
92. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454.
93. Wang L., et al. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg 2010, 34(5):1059-1065.
94. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT01313416&Search=Search.
95. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133.
96. Beatty G.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616.
97. ClinicalTrials.gov [homepage on the Internet]. Identifier: Available from: http://www.clinicaltrials.gov/ct2/show/NCT01456585?term=CP-870%2C893&rank=2.
98. Dannull J., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115(12):3623-3633.
99. Rasku M.A., et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6:12.
100. Attia P., et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28(6):582-592.
101. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009, 1174:99-106.
102. Chen C.A., et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010, 18(6):1233-1243.
103. Leao I.C., et al. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci 2008, 1(3):228-239.